Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

SurModics and NuPathe partner on long-acting Parkinsonís treatment
December 2009
SHARING OPTIONS:

EDEN PRAIRIE, Minn.óSurModics Inc., a provider of drug delivery and surface modification technologies to the healthcare industry, and NuPathe Inc., a neuroscience-focused specialty pharmaceutical company, announced in November that they signed a license agreement for NP201, the first long-acting treatment available in broadly acceptable dose form that maintains the potential to provide sustained relief from Parkinson's disease without motor response complications. NP201 leverages NuPathe's long-acting delivery technology and SurModics' biodegradable polymer matrix implant technology to achieve optimal drug release over an extended period of time. Under the licensing agreement, NuPathe will lead and fund development and commercialization. SurModics will provide technical and manufacturing expertise and will be eligible to receive licensing fees and milestone payments related to development of products for the treatment of Parkinson's disease and other clinical indications. SurModics will also receive royalties on product sales. 


Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.